(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 29.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Alnylam Pharmaceuticals's revenue in 2025 is $2,348,099,000.On average, 12 Wall Street analysts forecast ALNY's revenue for 2025 to be $380,898,396,935, with the lowest ALNY revenue forecast at $362,727,470,487, and the highest ALNY revenue forecast at $447,280,431,695. On average, 12 Wall Street analysts forecast ALNY's revenue for 2026 to be $509,859,819,362, with the lowest ALNY revenue forecast at $426,040,162,476, and the highest ALNY revenue forecast at $814,601,485,268.
In 2027, ALNY is forecast to generate $666,884,866,003 in revenue, with the lowest revenue forecast at $545,215,153,678 and the highest revenue forecast at $1,222,417,262,054.